Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Ho

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Cancer|July 9, 2020
The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancerJung Julie Kang, Richard J Wong, Eric J Sherman, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
JAMA Otolaryngology-- Head & Neck Surgery|November 26, 2025
Osteoradionecrosis After Intensity-Modulated Radiation Therapy or Proton Therapy in Oropharyngeal CarcinomaFan Yang, Edward Christopher Dee, Annu Singh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
Nature Medicine|April 24, 2019
Immunogenic neoantigens derived from gene fusions stimulate T cell responsesWei Yang, Ken-Wing Lee, Raghvendra M Srivastava, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
JAMA Network Open|January 23, 2023
Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell CarcinomaAnna Lee, Robbie Woods, Amgad Mahfouz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyChrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Merkel cell carcinoma, version 1.2014Christopher K Bichakjian, Thomas Olencki, Murad Alam, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Cancer|July 9, 2020
The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancerJung Julie Kang, Richard J Wong, Eric J Sherman, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
JAMA Otolaryngology-- Head & Neck Surgery|November 26, 2025
Osteoradionecrosis After Intensity-Modulated Radiation Therapy or Proton Therapy in Oropharyngeal CarcinomaFan Yang, Edward Christopher Dee, Annu Singh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
Nature Medicine|April 24, 2019
Immunogenic neoantigens derived from gene fusions stimulate T cell responsesWei Yang, Ken-Wing Lee, Raghvendra M Srivastava, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
JAMA Network Open|January 23, 2023
Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell CarcinomaAnna Lee, Robbie Woods, Amgad Mahfouz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyChrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Merkel cell carcinoma, version 1.2014Christopher K Bichakjian, Thomas Olencki, Murad Alam, et al.
Pageof 12